LC-Plasma on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Diseases

Inclusion Criteria: * Individuals who can provide a signed and dated informed consent form after confirming their willingness to participate. * Individuals willing to comply with all study procedures during the study period, including daily monitoring record compliance, cooperating with blood and urine sample collection and performing regular RATs. * Healthy people living in Australia aged 18-60 (both men and women). * Individuals who have received at least two doses of a SARS-CoV-2 vaccine, with at least two weeks having passed since the last dose. * Individuals who are not currently infected with SARS-CoV-2 and, if previously infected, have recovered and have been infection-free for at least four weeks. * Individuals who do not have any chronic or acute illnesses, including respiratory and/or gastrointestinal and/or other diseases, (e.g. hypertension, IBS, IBD, SLE, cancer, asthma, primary or secondary immunodeficiencies etc.), at the time of enrolment. Exclusion Criteria: * Individuals medically prescribed medications that would affect the immune and/or the inflammatory response. * Individuals deemed unsuitable for participation by Griffith CTU staff and/or the study clinician. * Active smokers/vapers and/or individuals with nicotine or drug habits. * Individuals currently participating in (or planning to participate in) other clinical trials. * Women who are pregnant, planning to become pregnant during the study period, or are currently breastfeeding. * Individuals unable to abstain from alcohol for two days prior to blood and urine sample collection. * Individuals unable to refrain from consuming other lactic acid bacteria supplements. * Individuals who are known to be HIV, HTLV-1, or HCV positive (based on answers to the enrolment questionnaire).